INTRODUCTION:
l In recent years (2011 -2014) various new oncology therapies were launched and evaluated by the different market access authorities.
l
The international Prismaccess database includes all evaluations and decisions by the respective authorities in France, Germany and the UK. 
METHODS:
l For all decisions for new oncology therapies which were evaluated by the authorities in France, Germany and UK has been systematically searched for. 
RESULTS:
l In total there were 20 new oncology therapies being evaluated in the three countries. Germany l 17 were positive in Germany (n=1 'significant'; n=8 'considerable'; n=7 'minor'; n=1 'non-quantifiable' added benefit).
l Two products have been overall appraised negative (TAFINLAR; TEYSUNO). In ten of the products for one or more subgroups the appraisal has been negative. 
